Core Viewpoint - The establishment of a regular communication mechanism between relevant authorities and the China Securities Regulatory Commission (CSRC) aims to support the capital market in Shenzhen's comprehensive reform, with expectations for a series of reforms, including the return of companies listed on the Hong Kong Stock Exchange to the Shenzhen Stock Exchange [1][2] Group 1: Market Dynamics - The Shenzhen authorities have enhanced communication with various ministries since the issuance of the "Opinions on Deepening the Reform and Innovation of Shenzhen's Comprehensive Reform Pilot" [2] - The market anticipates that the return of companies from the Guangdong-Hong Kong-Macao Greater Bay Area to the Shenzhen Stock Exchange will provide more investment opportunities for investors and contribute to the growth of the A-share market [2][3] Group 2: Eligible Companies - There are over 250 companies listed on the Hong Kong Stock Exchange that are registered in the Guangdong-Hong Kong-Macao Greater Bay Area, with 30 already listed on the A-share market and 220 yet to return [3] - Among the 220 companies, the top three by market capitalization are AIA Group (737.19 billion HKD), Hong Kong Exchanges and Clearing (548.47 billion HKD), and Bank of China (Hong Kong) (379.03 billion HKD) [3] Group 3: Regulatory Framework - The National Development and Reform Commission has indicated support for eligible Hong Kong-listed companies to issue depositary receipts on the Shenzhen Stock Exchange, clarifying the path for different types of Hong Kong companies to return to A-shares [3][4] - The current rules require that red-chip companies seeking secondary listings on the Shenzhen Stock Exchange must have a market capitalization of at least 200 billion CNY and possess strong technological innovation capabilities [5][6] Group 4: Economic Implications - The return of Hong Kong-listed companies to the Shenzhen Stock Exchange is expected to enrich the industry matrix and enhance the valuation system of the A-share market, potentially attracting international capital [6][7] - The dual listing on both the Shenzhen and Hong Kong exchanges may facilitate the return of offshore RMB, thereby promoting the internationalization of the RMB and enhancing cross-border capital flow [7]

Summary of Key Points from the Conference Call of 康方生物 Company Overview - 康方生物 is focused on the development of innovative cancer therapies, particularly in the field of immunotherapy, with key products including 依沃西单抗 (AK112) and 卡度尼利单抗 (AK104) [2][3][11]. Industry Insights - The stock price of 康方生物 is highly sensitive to the clinical data of its products, particularly 依沃西单抗. Significant fluctuations were noted following the release of clinical trial results [2][5]. Core Products and Market Potential - **依沃西单抗 (AK112)**: - Approved for non-small cell lung cancer (NSCLC) with a projected domestic revenue of approximately 100 billion RMB and an overseas peak sales potential of 10 billion USD [3][10]. - Clinical trial results from the Harmony Two study showed a progression-free survival (PFS) of 11.1 months compared to 5.82 months for the control group, with a PFS hazard ratio (HR) of 0.51 and overall survival (OS) HR of 0.777 [2][9]. - **卡度尼利单抗 (AK104)**: - Approved for cervical and gastric cancer, with an annual treatment cost of about 150,000 RMB. It fills a significant gap for patients with low or negative PD-L1 expression [2][7]. - In gastric cancer, the OS HR for patients with CPS < 10 and CPS < 5 was 0.72 and 0.75, respectively, indicating efficacy in low PD-L1 expressing patients [8]. - The peak revenue potential in China is estimated at 50 billion RMB [3]. Clinical Trial Performance - 依沃西单抗 has shown consistent efficacy across various clinical trials, including a PFS HR of 0.52 and OS HR of 0.79 in trials involving EGFR TKI refined NSCLC patients [6][10]. - AK104 has demonstrated significant clinical value in treating gastric and cervical cancers, particularly in populations with low PD-L1 expression [8]. Future Development Directions - 康方生物 plans to expand the indications for 依沃西单抗 to include biliary tract cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, pancreatic cancer, and colorectal cancer [3][11]. - The company aims to solidify its position as a leader in the immunotherapy space by addressing unmet clinical needs and expanding its product offerings across various stages of treatment [11]. Market Valuation - The overall target market capitalization for 康方生物 is projected to reach approximately 1,600 billion HKD, driven by the anticipated revenues from its key products [4].

Market Overview - On July 22, the Hang Seng Index rose by 0.54%, closing at 25,130.03 points, with a total net inflow of HKD 2.717 billion through the southbound trading channel [1] - The total trading volume for the southbound trading was HKD 162.832 billion, with a net buy of HKD 2.717 billion [1] Southbound Trading Details - In the Shanghai-Hong Kong Stock Connect, the trading volume was HKD 103.231 billion with a net buy of HKD 2.985 billion, while the Shenzhen-Hong Kong Stock Connect had a trading volume of HKD 59.600 billion with a net sell of HKD 0.267 billion [1] - The top active stocks in the Shanghai-Hong Kong Stock Connect included Dongfang Electric with a trading volume of HKD 4.374 billion, followed by Huaxin Cement and Tencent Holdings with trading volumes of HKD 3.489 billion and HKD 2.647 billion, respectively [1] Stock Performance - China Life had the highest net buy amount of HKD 0.879 billion, with a closing price increase of 4.23% [1] - Semiconductor Manufacturing International Corporation (SMIC) recorded the highest net sell amount of HKD 0.267 billion, with a closing price increase of 2.75% [1] Shenzhen-Hong Kong Stock Connect Highlights - In the Shenzhen-Hong Kong Stock Connect, SMIC led in trading volume with HKD 1.979 billion, followed by Meituan and Alibaba with trading volumes of HKD 1.833 billion and HKD 1.739 billion, respectively [2] - SMIC also had the highest net buy amount of HKD 0.779 billion, while Tencent Holdings had the highest net sell amount of HKD 0.373 billion, with a closing price increase of 0.86% [2] Active Stocks Summary - The top active stocks in the southbound trading on July 22 included: - Dongfang Electric: Trading volume of HKD 4.374 billion, net buy of HKD 0.165 billion, price change of -2.84% [2] - Huaxin Cement: Trading volume of HKD 3.489 billion, net buy of HKD 0.313 billion, price change of -15.05% [2] - Tencent Holdings: Trading volume of HKD 2.647 billion, net buy of HKD 0.027 billion, price change of 0.86% [2] - SMIC: Trading volume of HKD 2.590 billion, net sell of HKD 0.267 billion, price change of 2.75% [2] - China Life: Trading volume of HKD 1.919 billion, net buy of HKD 0.879 billion, price change of 4.23% [2]

从连续性进行统计， 有2只股获南向资金连续3天以上净买入，连续净买入天数较多的有阿里巴巴-W、 中芯国际，连续净买入天数分别为4天、4天。以其间净买入金额统计，净买入金额最多的是中芯国际， 合计净买入为11.76亿港元，其次是阿里巴巴-W合计净买入为5.78亿港元。（数据宝） 7月22日南向资金成交活跃股 | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 02628 | 中国人寿 | 191863.98 | 87850.80 | 4.23 | | 00939 | 建设银行 | 202947.92 | 75542.83 | -1.19 | | 00981 | 中芯国际 | 456868.79 | 51150.55 | 2.75 | | 03690 | 美团-W | 400715.04 | 38247.29 | -1.38 | | 06655 | 华新水泥 | 482203.23 | 33955.91 | -15.05 | | 03339 | 中国龙工 | 327254.27 | 26330.16 | ...

Group 1 - On July 22, 2025, the top three companies by trading volume in the Hong Kong Stock Connect (southbound) were Dongfang Electric (01072) with a trading volume of 4.374 billion, Huaxin Cement (06655) with 3.489 billion, and Tencent Holdings (00700) with 2.647 billion [1] - In the Shenzhen-Hong Kong Stock Connect (southbound), the top three companies by trading volume were SMIC (00981) with 1.979 billion, Meituan-W (03690) with 1.833 billion, and Alibaba-W (09988) with 1.739 billion [1] Group 2 - The top active companies in the Hong Kong Stock Connect (southbound) included Dongfang Electric (01072) with a net buy of 0.165 billion, Huaxin Cement (06655) with 0.313 billion, and Tencent Holdings (00700) with 0.271 billion [2] - In the Shenzhen-Hong Kong Stock Connect (southbound), SMIC (00981) had a net buy of 0.779 billion, while Meituan-W (03690) had a net sell of 0.050 billion [2]

| 6.08亿 | 4.51亿 | 10.59亿 +1.57亿 | | --- | --- | --- | | 小米集团-W 5.07亿 | 5.00亿 | 10.07亿 +670.13万 | | 中国龙工 4.09亿 | 4.10亿 | 8.18亿 -86.81万 | | 康方生物 HK 09926 HK 01810 HK 03339 | | | 智通财经APP获悉，7月22日港股市场，北水成交净买入27.17亿港元，其中港股通(沪)成交净买入29.85 亿港元，港股通(深)成交净卖出2.67亿港元。 北水净买入最多的个股是中国人寿(02628)、建设银行(00939)、中芯国际(00981)。北水净卖出最多的个 股是国泰君安国际(01788)、腾讯(00700)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 东方电气 | 22.70亿 | 21.05 乙 | 43.74 Z | | HK 01072 | | | +1.65 亿 | | 华新水泥 | 19.01亿 | 15.88 亿 | 34.89 乙 | | ...

Core Insights - Public funds continued to increase their holdings in Hong Kong stocks in Q2 2025, with the market value of Hong Kong stocks in the sample of actively managed equity funds rising to 20.0%, up from 19.2% in Q1 2025 [6][10] - The increase in holdings was primarily in small and medium-sized Hong Kong stocks, with the Hang Seng Small Cap Index's component stocks' market value share in the total Hong Kong stock holdings of funds increasing by 5.6 percentage points [6][10] - Sector-wise, public funds mainly increased their positions in the pharmaceutical, light manufacturing, non-bank financials, and banking sectors, corresponding to themes of innovative drugs, new consumption, and dividends [6][10] Fund Holdings Analysis - The report indicates a significant shift in fund holdings, with a reduction in the technology sector, particularly in internet and automotive stocks, which had previously seen substantial gains [6][10] - The technology sector's market value share in fund holdings decreased by 3.7 percentage points, while the media and retail sectors also saw declines [10][12] - Conversely, the consumer sector saw an increase of 3.8 percentage points in market value share, indicating a strategic pivot towards consumer-related investments [10][12] Specific Stock Movements - Notable changes in specific stock holdings include Tencent Holdings decreasing from 21.5% to 17.8%, while Alibaba's share dropped from 10.6% to 6.3% [12] - In contrast, stocks like Kuaishou and Pop Mart saw increases in their holdings, reflecting a shift towards emerging consumer brands [12] - The report highlights a significant increase in holdings for companies like Xinda Biopharmaceuticals, which rose from 1.2% to 3.5%, indicating a growing interest in innovative healthcare solutions [12]

Group 1 - The core viewpoint of the article highlights that innovative drugs have become a key source of returns for public funds in 2023, with the Hong Kong stock market's innovative drug index surging by 93.94% as of July 21 [1] - A significant number of funds have reported exceptional performance, with six funds achieving over 100% returns, all heavily invested in innovative drugs [2][3] - The article emphasizes that the majority of funds with returns exceeding 80% are either actively or passively invested in the innovative drug sector [3] Group 2 - The pharmaceutical industry has faced a downturn since 2021, with the pharmaceutical and biotechnology index dropping over 40.19% and the Hong Kong innovative drug index declining by 59.24% over four years [5] - Despite the previous downturn, many funds have recovered losses from 2024 and generated substantial returns due to the recent surge in innovative drugs [6] - The article suggests that the current market rally may only be a temporary boost for thematic funds, and it is essential to evaluate long-term performance during previous downturns [7][8] Group 3 - The article provides detailed performance data of various funds, highlighting the returns of specific funds managed by notable fund managers, such as Zhang Wei and Jin Xiaofei, who have achieved significant returns through strategic investments in innovative drugs [11][37] - Zhang Wei's management of the Huatai-PineBridge Hong Kong Advantage Fund has yielded a return of 138.23% since its inception, while Jin Xiaofei's Penghua Medical Technology Fund has achieved a return of 260.27% since he took over [11][37] - The article discusses the investment strategies of these fund managers, focusing on their ability to identify undervalued innovative drug companies and their proactive adjustments to market conditions [15][56] Group 4 - The article mentions specific innovative drug companies that have performed well, such as Bai Li Tianheng and Hai Si Ke, which have seen significant stock price increases due to successful transitions from generic to innovative drug companies [24][63] - It highlights the importance of understanding the competitive landscape and long-term industry trends when investing in innovative drugs, as emphasized by fund managers like Zhao Wei [56][58] - The article concludes with a positive outlook for the innovative drug sector, suggesting that supportive policies and market conditions may lead to a recovery and growth in the coming years [34][49]

7月22日，港股创新药再度走强，高纯度+高弹性标的港股通创新药ETF（520880）场内价格现涨逾 3%，再攀新高。 | 序号 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 1513 | 丽珠医药 | 1 | 40.500 | 4 200 | | | 2 | 3933 | 联邦制药 | | 16.640 | 1.220 | 7.91% | | 3 | 9688 | 更鼎医药 | | 29.200 | 1.850 | 6.76% | | 4 | 1548 | 金斯瑞生物科技 | | 17.440 | 1.020 | 6.21% | | 5 | 9969 | 诺诚健华 | Mr. | 19.020 | 0.840 | 4.62% | | 6 | 9926 | 康方生物 | While | 146.900 | 6.400 | 4.56% | | 7 | 2162 | 康诺亚-B | | 62.650 | 2.550 | 4 74% | | 8 | 6990 | 科伦博泰生物-E W | | 39 ...

Group 1 - The Hang Seng Healthcare Index (HSHCI) has shown a strong increase of 2.14%, with notable gains from stocks such as Livzon Pharmaceutical (up 11.57%) and United Laboratories (up 7.00) [3] - The Hang Seng Healthcare ETF (513060) has risen by 2.02%, with a recent price of 0.66 yuan, and has accumulated an 8.95% increase over the past week, ranking in the top third among comparable funds [3] - The trading activity of the Hang Seng Healthcare ETF is robust, with a turnover rate of 10.09% and a transaction volume of 840 million yuan, indicating active market participation [3] Group 2 - The 11th batch of national drug procurement has officially launched, involving 55 varieties, signaling a positive shift in procurement policies favoring innovative drugs [4] - The procurement policy emphasizes "no procurement for new drugs" and optimizes selection criteria, enhancing protection for innovative drugs and promoting a healthier market ecosystem for generic drugs [4] - The stable operation of the national medical insurance fund, projected to reach total revenue of 34,913.37 billion yuan by the end of 2024, supports the accessibility and market demand for innovative drugs [5] Group 3 - The Hang Seng Healthcare ETF has seen a significant growth in scale, increasing by 221 million yuan over the past two weeks, ranking in the top third among comparable funds [5] - The ETF's financing activities are notable, with a latest financing purchase amount of 160 million yuan and a financing balance of 231 million yuan [5] - The ETF has achieved a net value increase of 30.39% over the past two years, with a maximum monthly return of 28.34% since inception [5] Group 4 - The Hang Seng Healthcare ETF has a Sharpe ratio of 2.22 over the past year, indicating strong risk-adjusted returns [6] - The ETF has the lowest relative drawdown among comparable funds, with a drawdown of 0.52% year-to-date [6] - The ETF's management fee is 0.50%, and its tracking error is 0.060%, the highest tracking precision among comparable funds [6] Group 5 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 60.73% of the index, including companies like BeiGene and WuXi Biologics [7]